Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Stomach cancer should no longer be considered a disease only of older people, and patients under 40 with chronic digestive symptoms should be more actively investigated – especially if they are of Latin American ethnicity.
Around 3,500 oncology professionals and researchers from around the world will learn about the latest advances in the field at the 21st ESMO World Congress on Gastrointestinal Cancer taking place in Barcelona, Spain, from 3 to 6 July 2019.
An international group of researchers has found that antibodies to the human papilloma virus type 16 develop in the body between six to 40 years prior to a clinical diagnosis of throat cancer, and their presence indicates a strong increased risk of the disease.
ESMO, the leading European professional organisation for medical oncology, has announced that the ESMO Congress 2021 will take place from 17 to 21 September 2021 at the Paris Expo Porte de Versailles, France.
De-escalation approaches in the treatment of women with HER2 positive breast cancer need to be personalised
Breast cancer in young women is characterised by more aggressive biological features as compared to those arising in older patients
Therapeutic innovations should go hand in hand with a multidisciplinary, fully integrated approach to patient care is the reminder issued by Prof Giuseppe Curigliano
A global survey of HER2 testing has raised questions about how resources should be spent on potentially lifesaving HER2 targeted therapies for breast cancer
Continuous chemotherapy shows greater benefit in patients with advanced breast cancer
Innovative breast cancer treatment will be discussed during the first ESMO Breast Cancer Congress in Berlin
Maintenance immunotherapy fails to improve survival in extensive-stage small cell lung cancer (SCLC), according to late-breaking results from the CheckMate 451 study to be presented today at the European Lung Cancer Congress 2019.
Two studies to be reported at ELCC 2019 provide new insights on the efficacy and safety of immunotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC)
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
